BPH Global Ltd - Asset Resilience Ratio
BPH Global Ltd (BP8) has an Asset Resilience Ratio of 33.28% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how BPH Global Ltd's Asset Resilience Ratio has changed over time. Check BPH Global Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down BPH Global Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BPH Global Ltd (BP8) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$630.00K | 33.28% |
| Total Liquid Assets | AU$630.00K | 33.28% |
Asset Resilience Insights
- Very High Liquidity: BPH Global Ltd maintains exceptional liquid asset reserves at 33.28% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
BPH Global Ltd Industry Peers by Asset Resilience Ratio
Compare BPH Global Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Alkem Laboratories Limited
NSE:ALKEM |
Drug Manufacturers - Specialty & Generic | 31.91% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 28.06% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Annual Asset Resilience Ratio for BPH Global Ltd (2016–2023)
The table below shows the annual Asset Resilience Ratio data for BPH Global Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-06-30 | 29.99% | AU$630.83K ≈ $446.35K |
AU$2.10 Million ≈ $1.49 Million |
+20.99pp |
| 2022-06-30 | 8.99% | AU$685.56K ≈ $485.08K |
AU$7.62 Million ≈ $5.39 Million |
-47.94pp |
| 2021-06-30 | 56.93% | AU$5.26 Million ≈ $3.72 Million |
AU$9.23 Million ≈ $6.53 Million |
-28.68pp |
| 2020-06-30 | 85.61% | AU$866.83K ≈ $613.34K |
AU$1.01 Million ≈ $716.46K |
+7.41pp |
| 2019-06-30 | 78.19% | AU$1.90 Million ≈ $1.35 Million |
AU$2.43 Million ≈ $1.72 Million |
+9.51pp |
| 2018-06-30 | 68.69% | AU$1.09 Million ≈ $768.68K |
AU$1.58 Million ≈ $1.12 Million |
+29.01pp |
| 2017-06-30 | 39.67% | AU$1.04 Million ≈ $739.09K |
AU$2.63 Million ≈ $1.86 Million |
+39.32pp |
| 2016-06-30 | 0.35% | AU$17.14K ≈ $12.13K |
AU$4.88 Million ≈ $3.45 Million |
-- |
About BPH Global Ltd
BPH Global Ltd, together with its subsidiaries, engages in sourcing, producing, marketing, and selling traditional medicines in Australia, Singapore, China, and Southeast Asia. The company's products include raw bird's nest and processed bird's nest products, and Caulerpa Lentillifera, sea grapes and seaweeds. Its products are used in the food, nutrition, healthcare, health supplements, cosmetics… Read more